Hiroyuki Hisamichi

Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure–activity relationships of pyrimidine-5-carboxamide derivatives

Hiroyuki Hisamichi, Ryo Naito, Akira Toyoshima et al. · Bioorganic & Medicinal Chemistry · 2005 · 54 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2

Ikumi Kuriwaki, Minoru Kameda, Hiroyuki Hisamichi et al. · Bioorganic & Medicinal Chemistry · 2020 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-activity Relationships of Cephalosporins Having a (Dimethylisoxazolidinio)vinyl Moiety at Their 3-Position.

RYUICHIRO HARAI, Kenichiro Sakamoto, Hiroyuki Hisamichi et al. · The Journal of Antibiotics · 1996 · 28 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +12

YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors

Nobuaki Amino, Yukitaka Ideyama, Mayumi Yamano et al. · Clinical Cancer Research · 2006 · 24 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Synthetic Studies on Selective Type 4 Phosphodiesterase (PDE 4) Inhibitors. 1. Structure-Activity Relationships and Pharmacological Evaluation of 1,8-Naphthyridin-2(1H)-one Derivatives.

Kazuhisa Takayama, Masahiro Iwata, Hiroyuki Hisamichi et al. · Chemical and Pharmaceutical Bulletin · 2002 · 16 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13